Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 25:10:1531.
doi: 10.3389/fonc.2020.01531. eCollection 2020.

Impact of Sex and Smoking on the Efficacy of EGFR-TKIs in Terms of Overall Survival in Non-small-Cell Lung Cancer: A Meta-Analysis

Jian Xiao  1   2 , Liang Zhou  3   4   5 , Bixiu He  1   2 , Qiong Chen  1   2
Affiliations

Impact of Sex and Smoking on the Efficacy of EGFR-TKIs in Terms of Overall Survival in Non-small-Cell Lung Cancer: A Meta-Analysis

Jian Xiao et al. Front Oncol. .

Abstract

Background: To comprehensively understand the impact of sex and smoking on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in terms of overall survival (OS) in non-small-cell lung cancer (NSCLC). Methods: PubMed, Cochrane Library, Embase, and Scopus were searched from inception to March 17, 2019. OS was analyzed based on hazard ratios (HRs) and 95% confidence intervals (CIs) and estimated using the random effects model. Results: Our meta-analysis included 22 studies involving 11,874 patients. In the primary analysis, we found no statistically significant efficacy difference for EGFR-TKI intervention between females and males (pooled HR 0.95, 95% CI 0.87-1.04, P = 0.30) and no obvious efficacy difference between never smokers and ever smokers (pooled HR 0.91, 95% CI 0.76-1.09, P = 0.31). In the subgroup analysis of placebo control treatment, we found that female NSCLC patients who received EGFR-TKI therapy had a longer OS than male patients (pooled HR 0.86, 95% CI 0.75-1.00, P = 0.04), while smoking status showed no significant effect on the efficacy of EGFR-TKI treatment in terms of the OS of NSCLC patients in all subgroup analyses. Conclusion: The efficacy of EGFR-TKI therapy for NSCLC patients is independent of smoking status but dependent on sex, and females have a longer OS than males.

Keywords: epidermal growth factor receptor-tyrosine kinase inhibitor; meta-analysis; non-small-cell lung cancer; overall survival; sex.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of the study selection.
Figure 2
Figure 2
Forest plot of the pooled analysis of the interaction hazard ratios of sex.
Figure 3
Figure 3
Forest plot of the pooled analysis of the interaction hazard ratios of smoking status.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. (2019) 69:7–34. 10.3322/caac.21551 - DOI - PubMed
    1. Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2014) 25(Suppl. 3):iii27–39. 10.1093/annonc/mdu199 - DOI - PubMed
    1. Ferketich AK, Niland JC, Mamet R, Zornosa C, D'Amico TA, Ettinger DS, et al. . Smoking status and survival in the national comprehensive cancer network non-small cell lung cancer cohort. Cancer. (2013) 119:847–53. 10.1002/cncr.27824 - DOI - PubMed
    1. Hsu LH, Chu NM, Liu CC, Tsai SY, You DL, Ko JS, et al. . Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor? Lung Cancer. (2009) 66:262–7. 10.1016/j.lungcan.2009.01.020 - DOI - PubMed
    1. Liu TC, Jin X, Wang Y, Wang K. Role of epidermal growth factor receptor in lung cancer and targeted therapies. Am J Cancer Res. (2017) 7:187–202. - PMC - PubMed

Publication types